Shaanxi Meibang Pharmaceutical Group Co., Ltd.
605033.SS · SHH
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.20 | -0.70 | -2.60 | 0.62 |
| FCF Yield | 7.40% | 5.46% | 0.74% | -5.96% |
| EV / EBITDA | 24.26 | 22.85 | 12.45 | 21.89 |
| Quality | ||||
| ROIC | 2.39% | 3.77% | 10.30% | 10.53% |
| Gross Margin | 28.55% | 31.61% | 41.63% | 38.27% |
| Cash Conversion Ratio | 7.61 | 5.82 | 0.87 | -0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.76% | -6.03% | 16.81% | 17.78% |
| Free Cash Flow Growth | -7.26% | 665.68% | 107.95% | -1,734.93% |
| Safety | ||||
| Net Debt / EBITDA | -3.29 | -5.71 | -1.26 | -1.47 |
| Interest Coverage | 3,232.64 | 99.37 | 128.45 | 35.68 |
| Efficiency | ||||
| Inventory Turnover | 2.39 | 1.35 | 1.13 | 0.93 |
| Cash Conversion Cycle | 9.15 | 216.54 | 326.71 | 416.84 |